A 47-Year-Old Woman with Metastatic Melanoma

Hussein Tawbi, MD, PhD reviews a case study of a 47-year-old woman with BRAF-mutated metastatic melanoma and discusses his approach to workup, including biomarker testing, for patients with the disease.

Subject matter expert provides a comprehensive overview of available first-line therapy options for patients with unresectable or metastatic melanoma and a BRAF mutation.

Data-driven clinical insights concerning the selection of effective first-line treatment options for patients with BRAF-mutated metastatic melanoma, with a focus on the DREAMseq trial.

Revisiting the patient case study, Dr Hussein Tawbi shares how he might approach systemic first-line treatment in this situation, with a focus on limiting drug toxicity.

Clinical insights regarding the treatment of patients with BRAF-mutated metastatic melanoma presenting with symptomatic/asymptomatic brain metastases.

Thoughtful comments from Dr Hussein Tawbi on setting first-line treatment goals and typical treatment responses in patients with unresectable or metastatic melanoma.

Discussion centered around planning for, managing, and overcoming adverse effects in the first-line systemic therapy setting for melanoma.

Hussein Tawbi, MD, PhD closes the discussion by outlining current unmet needs in the unresectable metastatic melanoma treatment landscape.